MAGEA3 and non-small cell lung carcinoma: The large phase 3 MAGRIT trial, investigating the efficacy of a shared antigen vaccine, MAGE-A3, as adjuvant therapy for patients with resected NSCLC who tested positive for MAGE-A3, yielded with negative results regarding DFS, its primary endpoint, and OS, with several other negative trials following [67].